Abstract
During the process of tumorigenesis, certain cancers are known to develop deficiencies in one or more major pathways of DNA damage repair, rendering them critically dependent on alternative repair processes for maintaining genomic integrity and viability. Targeting these alternative DNA repair mechanisms is a potentially highly-specific anticancer strategy, as their inhibition is theoretically toxic only to tumor cells and not to normal tissues. We will review here the rationale behind this strategy and provide examples of its application. We will also discuss several as yet unanswered questions surrounding this strategy, including whether human cancers frequently harbor synthetically lethal interactions in DNA repair and, if so, how patients might be identified who would benefit from targeting such interactions.
Keywords: Radiation, chemotherapy, DNA repair, double-strand break repair, non-homologous end joining, homologous recombination, Tumorigenesis, Homologous recobmination, Mutation, Tumor-specific phenotype, PARP inhibitor, BRCA-defective tumors, Translocation, Genetic mutation, Amplification, Oncogenic stress, Cytotoxic drugs, Radiomimetics, NHEJ, PARP proteins, PARP inhibitors, Biomarkers, Oncology
Current Drug Targets
Title: Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Volume: 11 Issue: 10
Author(s): Benjamin J. Moeller, Wadih Arap and Renata Pasqualini
Affiliation:
Keywords: Radiation, chemotherapy, DNA repair, double-strand break repair, non-homologous end joining, homologous recombination, Tumorigenesis, Homologous recobmination, Mutation, Tumor-specific phenotype, PARP inhibitor, BRCA-defective tumors, Translocation, Genetic mutation, Amplification, Oncogenic stress, Cytotoxic drugs, Radiomimetics, NHEJ, PARP proteins, PARP inhibitors, Biomarkers, Oncology
Abstract: During the process of tumorigenesis, certain cancers are known to develop deficiencies in one or more major pathways of DNA damage repair, rendering them critically dependent on alternative repair processes for maintaining genomic integrity and viability. Targeting these alternative DNA repair mechanisms is a potentially highly-specific anticancer strategy, as their inhibition is theoretically toxic only to tumor cells and not to normal tissues. We will review here the rationale behind this strategy and provide examples of its application. We will also discuss several as yet unanswered questions surrounding this strategy, including whether human cancers frequently harbor synthetically lethal interactions in DNA repair and, if so, how patients might be identified who would benefit from targeting such interactions.
Export Options
About this article
Cite this article as:
J. Moeller Benjamin, Arap Wadih and Pasqualini Renata, Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011336
DOI https://dx.doi.org/10.2174/1389450111007011336 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry Deciphering the Influence of Cigarette Smoke Carcinogens on CNS Associated Biomolecules: A Computational Synergistic Approach
CNS & Neurological Disorders - Drug Targets Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Inhibitors of the Chemokine Receptor CXCR4: Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis
Letters in Drug Design & Discovery Evaluation of the <i>In Vivo</i> Acute Toxicity and <i>In Vitro</i> Hemolytic and Immunomodulatory Activities of the <i>Moringa oleifera</i> Flower Trypsin Inhibitor (MoFTI)
Protein & Peptide Letters Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Multiple Target-Specific Molecular Imaging Agents Detect Liver Cancer in a Preclinical Model
Current Molecular Medicine Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Current Cancer Therapy Reviews Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Inhibition of Human Melanoma Cell Replication Using Protein Transduction Technology with a Uracil-DNA Glycosylase Inhibitor
Letters in Drug Design & Discovery The Reciprocal Interaction: Chemotherapy and Tumor Microenvironment
Current Drug Discovery Technologies The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews